Stromal cells supporting cancer growth are emerging as importan targets for drugs and immunotherapies.

TK-002 is an innovative Cancer Vaccine vs a Stromal Antigen

• Identified by our group as novel target for immunotherapy
• Potential "Universal" Cancer Vaccine

Where we are:

• Preclinical studies completed
• Vectors (both Adeno and plasmid DNA) for human clinical use constructed
• Biomarker assay under advanced development

Preferred Cancer Targets

• Colon
• Prostate
• Stomach